Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis

Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis

BackgroundThe Assessment of SpondyloArthritis international Society-European Alliance of Associations for Rheumatology recommendations for axial spondyloarthritis (axSpA) management include patient assessment for biological disease-modifying antirheumatic drug (bDMARD) treatment response after at le...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Rheumatic & musculoskeletal diseases open 2024-07, Vol.10 (3), p.e004429
Hauptverfasser: Ramiro, Sofia, Lukas, Cédric, Bessette, Louis, Wickersham, Pendleton, Panni, Tommaso, Bolce, Rebecca, Liu-Leage, Soyi, Janos, Boris, Nissen, Michael J, Wei, James Cheng-­Chung
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - therapeutic use
Antirheumatic Agents - administration & dosage
Antirheumatic Agents - therapeutic use
Arthritis
Axial Spondyloarthritis
Axial Spondyloarthritis - drug therapy
Axial Spondyloarthritis - etiology
Biological Therapy
Clinical medicine
Cost analysis
Cytokines
Female
Humans
Interleukin-17
Kinases
Male
Middle Aged
Missing data
Monoclonal antibodies
Original Research
Patients
Radiography
Severity of Illness Index
Spondyloarthritis
Treatment Outcome
Tumor necrosis factor-TNF
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BackgroundThe Assessment of SpondyloArthritis international Society-European Alliance of Associations for Rheumatology recommendations for axial spondyloarthritis (axSpA) management include patient assessment for biological disease-modifying antirheumatic drug (bDMARD) treatment response after at least 12 weeks of treatment. The current treat-to-target strategy for axSpA is to achieve inactive disease (ID; Axial Spondyloarthritis Disease Activity Score (ASDAS)
ISSN:2056-5933
2056-5933
DOI:10.1136/rmdopen-2024-004429